Physician profile
Robert Wesley Benigar
NPI 1750392734
$9,630.06
in general payments reported to CMS, 2019-2025
38 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $475 · 2021: $1,657 · 2022: $1,124 · 2023: $1,535 · 2024: $1,760 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,969 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.75 |
| Education | $215.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.14 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,078.94 | 2019-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $916.91 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $670.68 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $596.71 | 2022-2025 | Azstarys |
| Lundbeck LLC | $549.49 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $458.86 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $399.25 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $343.99 | 2019-2025 | Trintellix |
| Allergan, INC. | $324.92 | 2019-2020 | |
| Noven Therapeutics, LLC | $257.67 | 2020-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $244.28 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $210.77 | 2021-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $191.32 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $188.68 | 2023-2024 | Quviviq |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $175.58 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $169.72 | 2019-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $167.80 | 2019-2023 | Belsomra |
| Neos Therapeutics, LP | $148.91 | 2021-2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $148.49 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $135.81 | 2021-2023 | Qelbree |
| Almatica Pharma LLC | $122.94 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $101.79 | 2019-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $96.32 | 2023-2025 | Sunosi, Auvelity |
| Tris Pharma INC | $83.03 | 2019-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $71.55 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $66.01 | 2019-2023 | Relexxii |
| Avanir Pharmaceuticals, INC. | $53.49 | 2019-2020 | |
| Amgen INC. | $47.63 | 2020-2021 | |
| Bausch Health US, LLC | $46.96 | 2019-2022 | |
| Shire North American Group INC | $45.22 | 2019 | |
| Eisai INC. | $34.43 | 2020-2021 | |
| Owp Pharmaceuticals, INC. | $23.09 | 2023 | Subvenite, Lamotrigine |
| Novo Nordisk INC | $22.89 | 2024 | |
| Sage Therapeutics, LLC | $18.45 | 2025 | Zurzuvae |
| Medtronic, INC. | $17.82 | 2022 | |
| Itamar Medical INC | $15.99 | 2024 | Watchpatone |
| Neuronetics, INC. | $9.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Benigar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.